Study to Evaluate Hemodynamic Effect of Different Loading Doses of Precedex in Post-surgical Intensive Care Unit (ICU) Patients
Phase 4, Open-Label Study Evaluating the Hemodynamic Effect of Differing Loading Regimens of Precedex in a Post-Surgical Intensive Care Patient Population
Sponsor: Hospira, now a wholly owned subsidiary of Pfizer
This observational or N/A phase trial investigates Intensive Care Unit and is currently completed. Hospira, now a wholly owned subsidiary of Pfizer leads this study, which shows 8 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
▶ Show 3 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
May 2017 — Apr 2018 [monthly]
Completed NA
-
Jan 2017 — May 2017 [monthly]
Completed NA
First recorded
Sep 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hospira, now a wholly owned subsidiary of Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Calgary, Canada , Edmonton, Canada , Halifax, Canada , Kingston, Canada , Kitchener, Canada , London, Canada , Montreal, Canada , Québec, Canada , Red Deer, Canada , Sherbrooke, Canada and 3 more locations